Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry
May 31, 2022 07:39 ET
|
Axsome Therapeutics, Inc.
NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Axsome, Humbl, Okta, and CareDx and Encourages Investors to Contact the Firm
May 29, 2022 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, May 29, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of...
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – AXSM
May 26, 2022 09:25 ET
|
The Rosen Law Firm PA
NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Axsome Therapeutics, Inc. (NASDAQ: AXSM) between December...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Upstart, Oscar Health, and Axsome and Encourages Investors to Contact the Firm
May 23, 2022 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Upstart, Oscar, and Axsome and Encourages Investors to Contact the Firm
May 18, 2022 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of...
Bragar Eagel & Squire, P.C. Is Investigating Verra, Cassava, Dentsply Sirona, and Axsome and Encourages Investors to Contact the Firm
May 11, 2022 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, May 11, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Verra Mobility Corp....
Bragar Eagel & Squire, P.C. Is Investigating Dentsply, Cassava, and Axsome and Encourages Investors to Contact the Firm
May 06, 2022 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, May 06, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Dentsply Sirona, Inc....
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Axsome Stockholders and Encourages Investors to Contact the Firm
April 27, 2022 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Axsome Therapeutics, Inc....
Moore Kuehn, PLLC Encourages Investors of ALEC, RETA, ASXM, and PTCT to Contact Law Firm
April 07, 2022 11:12 ET
|
Moore Kuehn
NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Alector, Inc. (NASDAQ: ALEC),...
Axsome Therapeutics to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome’s Leadership in Neuroscience
March 28, 2022 06:00 ET
|
Axsome Therapeutics, Inc.
Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) approved by the FDA to improve wakefulness in adults living with excessive daytime sleepiness associated...